Rare NRG1 Fusion Market Size in the 8MM Anticipated to Soar Dynamically with a CAGR of 19.0% During the Study Period 2018-2030 | DelveInsight

LAS VEGAS, March 18, 2021 -- DelveInsight's Rare NRG1 Fusion Market Insights report offers detailed information on current treatment practices, emerging drugs, Rare NRG1 Fusion market share of the individual therapies, current and forecasted Rare NRG1 Fusion market size from 2018 to 2030 segmented into 8MM (the USA, EU5 (the UK, Italy, Spain, France and Germany), Japan and China).

The report also covers the present Rare NRG1 Fusion treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that helps clients to curate the best of the opportunities, assesses the underlying potential of the market, and plans strategically to tackle market risks.

Some of the vital takeaways from the Rare NRG1 Fusion Market Report: 

• Although NRG1 Fusions are rare (i.e.reported incidence of ~0.2% across solid tumors) but potentially actionable oncogenic drivers in solid tumors. 
• The most commonly reported NRG1 fusion is CD74-NRG1 that is often found in patients with invasive mucinous adenocarcinomas (IMAs) of the lung.
• In the year 2020, the total Rare NRG1 Fusion incident cases were recorded to be approximately 12,934 in the 8MM in 8 selected potential solid tumor types, which are further expected to increase during the study period.
• Key pharma companies such as Rain Therapeutics (Tarloxotinib), Elevation Oncology (Seribantumab), Merus (Zenocutuzumab), Eli Lilly and Company (Mirikizumab), AVEO Oncology (AV-203), Hummingbird Bioscience (HMBD-001, preclinical phase), and several others are investigating their candidates in the Rare NRG1 Fusions market.
• According to the Rare NRG1 Fusion market analysis, the highest market size expected to be from the United States by 2030 owing to the higher patient pool and higher treatment cost followed by China
• Key Rare NRG1 Fusion pipeline therapies such as Tarloxotinib (Rain Therapeutics), MM-121/Seribantumab (Elevation Oncology), Zenocutuzumab/MCLA-128 (Merus), AV-203/CAN017 (CANbridge Pharmaceuticals/AVEO Oncology), among others are expected to get launched in the forecast period 2021-30. 
• Out of all the Rare NRG1 Fusion emerging therapies, Zenocutuzumab is expected to occupy the maximum share of the market owing to novel MoA, efficiency demonstrated in the ongoing trials and also the early mover advantage. Further, this therapy is in Phase II stage of clinical development leveraging its competitive advantage.
• Due to the relative novelty of mutation and lack of extensive research and development, the pipeline of rare NRG1 fusions is still evolving and most of the drugs are still in the very early phase of development.
• The market for NRG1 fusion is highly untapped and there is a huge opportunity for players to enter the market, owing to a bleak pipeline scenario as only a few companies are focused on developing a therapy for this indication and also the drugs can get the tumour-agnostic approval similar to Keytruda, Vitrakvi and Rozlytrek
• The pipeline of the Rare NRG1 Fusion Market is still in its infancy, however, is expected to evolve rapidly attributable to their occurrence in ~0.2% of solid tumors as well as certain invasive tumors including invasive mucinous adenocarcinoma subtype of the lung. 

Learn more about the report highlights @ Rare NRG1 Fusion Market Analysis and Forecast 

Rare NRG1 Fusion: Overview 

NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. These result in the activation of ErbB2-/ErbB3-mediated signalling pathways and may function as oncogenic drivers. 

Rare NRG1 Fusion Diagnosis 

NRG1-fusion proteins and genes in solid tumors can be detected with the help of several techniques such as immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. However, RNA sequencing remains the cornerstone of the detection of NRG1 gene fusions owing to higher sensitivity for genetic rearrangements as compared to DNA-based methods, which often do not cover the large introns in NRG1.

Rare NRG1 Fusion Epidemiology Segmentation 

Rare NRG1 Fusion Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 8MM spanning the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China segmented into:

• Total Incident Cases of NRG1 Fusion Across 8 Selected Potential Solid Tumors
• Total Stage-specific Cases of NRG1 Fusion
• Total Treated cases of NRG1 Fusion

For a comprehensive analysis, visit Rare NRG1 Fusion Epidemiology Trends 

Rare NRG1 Fusion Current Market State

The present treatment market for advanced tumors with NRG1 fusions comprises chemotherapy and/ or immunotherapy or novel anti-PD-1agents. Chemotherapy offers a systemic option as a treatment owing to its ability to kill metastasized cancerous cells. Other approaches involve radiation therapy and surgery, however, these only kill the tumor cells located at a single point at a particular time. 

Available Therapies for Solid Tumors Treatment

• Current/Off-label therapies
• Chemo immunotherapy
• Novel anti–PD-1 or anti–PD-L1 Agents, 
• Monoclonal antibodies (mAbs), and others. 

Reach out to us @ Rare NRG1 Fusion Marketed Therapies for more information on available treatment regimens 

However, the available treatment options fail to improve the quality and produce a suboptimal response in patients with NRG1 fusions. Analysis of the clinical reports and research claims the viability of NRG1 fusions as an actionable target in solid tumors, with responses seen on inhibition of ERBB family members.

NRG1 fusions are recurrent oncogenic drivers occurring in ~0.2% of solid tumors and enriched in certain tumor subtypes such as the invasive mucinous adenocarcinoma subtype of the lung. NRG1 fusions have been identified in over 10 solid tumor types, making it a strong candidate for a tumor-agnostic development approach.

Rare NRG1 Fusion Market Forecast

Currently, a few of the pharmaceutical companies have indulged themselves in the Rare NRG1 Fusion Market looking at the tremendous potential discovery of the NRG1 fusions are expected to offer.

Key pharmaceutical players such as Rain Therapeutics, Elevation Oncology, Merus, Eli Lilly and Company, AVEO Oncology, Hummingbird Bioscience, and several others are evaluating their candidates in different stages of clinical development for the management of Rare NRG1 Fusions. 

The dynamics of the Rare NRG1 Fusion Market are expected to revolutionize in the coming decade owing to the occurrence of such fusions in approximately 0.2% of the solid tumors and other invasive tumors. Rare NRG1 Fusion is nothing short of a potential agent for a tumor-agnostic development approach.

Further, the Rare NRG1 Fusion Market is still in its native state with only a handful of pharmaceutical companies operating in the domain, laying forward immense opportunities to other pharma companies to exploit. 

However, the rarity of fusions undoubtedly in itself is a challenge that makes it difficult for researchers to study and hold clinical trials; and their diversity of NRG1 fusions makes it difficult to diagnose or detect. Thus, standard diagnostic protocols are expected to act as a major driver in the steady, smooth growth of the Rare NRG1 Fusion Market size. 

Drop by to learn more about the future market trends @ Rare NRG1 Fusion Market Landscape and Forecast 

Rare NRG1 Fusion Pipeline Therapies 

• Tarloxotinib: Rain Therapeutics
• MM-121/Seribantumab: Elevation Oncology
• Zenocutuzumab/MCLA-128: Merus
• AV-203/CAN017: CANbridge Pharmaceuticals/AVEO Oncology

Gain rich insights into Rare NRG1 Fusion emerging therapies @ Rare NRG1 Fusion Drug Pipeline 

Scope of the Report 

Coverage: 8MM (the US, EU5, China and Japan)
Study Period: 2018-30
Key Companies: Rain Therapeutics, Elevation Oncology, Merus, Eli Lilly and Company, AVEO Oncology, Hummingbird Bioscience, among others.
Key Rare NRG1 Fusion Pipeline Therapies: Tarloxotinib, Seribantumab, Zenocutuzumab, Mirikizumab, AV-203, HMBD-001, among others. 
Rare NRG1 Fusion Market Segmentation: By Geography, By Rare NRG1 Fusion Therapies
Analysis: Comparative and conjoint analysis of Rare NRG1 Fusion emerging therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Case Studies
KOL's Views
Analyst's Views

Table of Contents 

Discuss the evolving trends of market landscape @ Rare NRG1 Fusion Market Management Market

Related Reports 

Non-Small Cell Lung Carcinoma Market | NSCLC Market  
DelveInsight's "NSCLC - Market Insights, Epidemiology, and Market Forecast-2030" report.

Non-Small Cell Lung Cancer Pipeline Therapies  
Read more about pipeline therapies targeting novel mutations. 

Advanced Pancreatic Cancer Market 
DelveInsight's "Advanced Pancreatic Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.

Gallbladder Cancer Market
DelveInsight's "Gallbladder Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report. 

Colorectal Cancer Market 
DelveInsight's "Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2030" report.

Advanced Recurrent Ovarian Cancer Market 
DelveInsight's "Advanced Recurrent Ovarian Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.

Bladder Cancer Market
DelveInsight's "Bladder cancer - Market Insights, Epidemiology, and Market Forecast-2030" report.

Muscle Invasive Bladder Cancer Market
DelveInsight's "Muscle Invasive Bladder cancer- Market Insights, Epidemiology, and Market Forecast-2030" report.

Marginal Zone Lymphoma Market
DelveInsight's 'Marginal Zone Lymphoma-Market Insights, Epidemiology, and Market Forecast–2030' report. 

Primary Immune Deficiency Market
DelveInsight's "Primary Immune Deficiency (PID) - Market Insights, Epidemiology, and Market Forecast-2030" report.

Stuttering Market
DelveInsight's "Stuttering Market Insights, Epidemiology, and Market Forecast-2030" report. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP